[go: up one dir, main page]

AR128391A1 - POL THETA INHIBITORS - Google Patents

POL THETA INHIBITORS

Info

Publication number
AR128391A1
AR128391A1 ARP230100220A ARP230100220A AR128391A1 AR 128391 A1 AR128391 A1 AR 128391A1 AR P230100220 A ARP230100220 A AR P230100220A AR P230100220 A ARP230100220 A AR P230100220A AR 128391 A1 AR128391 A1 AR 128391A1
Authority
AR
Argentina
Prior art keywords
pol theta
theta inhibitors
polq
dna polymerase
enzyme dna
Prior art date
Application number
ARP230100220A
Other languages
Spanish (es)
Inventor
Swaroop Kumar Venkata Satya Vakkalanka
Debnath Bhuniya
Venkata Satyanarayana Eleswarapu
Original Assignee
Rhizen Pharmaceuticals Ag
Incozen Therapeutics Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals Ag, Incozen Therapeutics Pvt Ltd filed Critical Rhizen Pharmaceuticals Ag
Publication of AR128391A1 publication Critical patent/AR128391A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos de fórmula (1), que poseen actividad inhibidora de la enzima ADN polimerasa theta (POLQ), métodos para su preparación, composiciones farmacéuticas que los contienen y su uso en el tratamiento o prevención de enfermedades o afecciones que involucran a la enzima ADN polimerasa theta (POLQ).The present invention relates to compounds of formula (1), which have inhibitory activity of the enzyme DNA polymerase theta (POLQ), methods for their preparation, pharmaceutical compositions containing them and their use in the treatment or prevention of diseases or conditions that They involve the enzyme DNA polymerase theta (POLQ).

ARP230100220A 2022-01-31 2023-01-30 POL THETA INHIBITORS AR128391A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202241005153 2022-01-31
IN202241006844 2022-02-09
IN202241007579 2022-02-12

Publications (1)

Publication Number Publication Date
AR128391A1 true AR128391A1 (en) 2024-04-24

Family

ID=85198983

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100220A AR128391A1 (en) 2022-01-31 2023-01-30 POL THETA INHIBITORS

Country Status (3)

Country Link
AR (1) AR128391A1 (en)
TW (1) TW202332442A (en)
WO (1) WO2023144793A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024197653A1 (en) * 2023-03-29 2024-10-03 Suzhou Eoc Medical Research Co., Ltd. Heterocyclic compounds and uses thereof
WO2024225803A1 (en) * 2023-04-27 2024-10-31 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the treatment and prophylaxis of cancer
TW202521116A (en) * 2023-11-24 2025-06-01 南韓商大熊製藥股份有限公司 Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer
GB202319863D0 (en) * 2023-12-21 2024-02-07 Breakpoint Therapeutics Gmbh Movel compounds, compositions and therapeutics uses thereof
WO2025201413A1 (en) * 2024-03-26 2025-10-02 上海湃隆生物科技有限公司 Selenium-containing heterocyclic compound and use thereof
CN119236073B (en) * 2024-08-28 2025-09-02 华中科技大学同济医学院附属协和医院 Use of POLQ inhibitors in the treatment of multiple myeloma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080330A (en) * 1975-06-23 1978-03-21 Delmar Chemicals Limited Phenylindolines and process for their production
US4584292A (en) * 1984-10-19 1986-04-22 Kotobuki Seiyaku Co., Ltd. Antihypertensive 1,5-benzothiazepine derivatives and compositions thereof
CN105330644B (en) * 2015-11-18 2017-12-19 中国农业大学 （The base of 1,2,3,4 tetrahydroquinoline 1）（Substituted pyrazolecarboxylic base）First ketone compounds and its application
AU2020215710A1 (en) 2019-01-30 2021-08-19 Ideaya Biosciences, Inc. Acetamido derivatives as DNA Polymerase Theta inhibitors
CA3127642A1 (en) 2019-01-31 2020-08-06 Ideaya Biosciences, Inc. Heteroarylmethylene derivatives as dna polymerase theta inhibitors
AU2020282768B2 (en) 2019-05-31 2023-09-14 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as DNA Polymerase Theta inhibitors
WO2021028643A1 (en) 2019-08-09 2021-02-18 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer
WO2021028644A1 (en) 2019-08-09 2021-02-18 Artios Pharma Limited Novel therapeutic use
GB201918587D0 (en) 2019-12-17 2020-01-29 Artios Pharma Ltd Novel compounds
WO2022026548A1 (en) * 2020-07-29 2022-02-03 Ideaya Biosciences, Inc. Acetamido-amino and acetamido-sulfur derivatives as dna polymerase theta inhibitors
WO2022026565A1 (en) * 2020-07-29 2022-02-03 Ideaya Biosciences, Inc. Cyclized acetamido derivatives as dna polymerase theta inhibitors

Also Published As

Publication number Publication date
TW202332442A (en) 2023-08-16
WO2023144793A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
AR128391A1 (en) POL THETA INHIBITORS
BR112022020841A2 (en) CAST TRICYCLIC KRAS INHIBITORS
ECSP21080740A (en) NLRP3 INFLAMASOME INHIBITORS
CL2020002146A1 (en) N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as hpki inhibitors to treat cancer.
BR112022001324A2 (en) Compound, pharmaceutical composition and method for treating a p38 map kinase-mediated disease in a subject in need thereof
BR112022000503A2 (en) Compounds Useful for Treating Influenza Virus Infections
BR112015022462A8 (en) acid inhibitors, pharmaceutical composition, method of inhibiting indolamine 2,3-dioxigenase activity and use of said inhibitors
BR112022012179A2 (en) SUBSTITUTED QUINAZOLINE COMPOUNDS USEFUL AS T-CELL ACTIVATORS
BR112022020147A2 (en) COMPOUNDS TO TREAT HUNTINGTON'S DISEASE
BR112016028642A2 (en) compound, pharmaceutical composition, method of treating a disease or condition, method of inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide, method of inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, and, use of a compound, salt, isomer or a pharmaceutically acceptable mixture thereof.
MX2021013422A (en) KCNT1 INHIBITORS AND METHODS OF USE.
CL2021002309A1 (en) Useful compounds in hiv therapy
BR112023015210A2 (en) CDK2 INHIBITORS AND METHODS OF USE THEREOF
BR112022013488A2 (en) SUBSTITUTED PYRAZOLO-PYRIMIDINES AND THEIR USE
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
BR112018072740A2 (en) zeste homolog 2 inhibitor enhancer
CA2990457C (en) Pyrrolidinyl and piperidinyl derivatives and pharmaceutical compositions thereof useful as gls1 inhibitors
BR112022018067A2 (en) PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS
CO2022016754A2 (en) Binding molecules for cancer treatment
BR112017028616A2 (en) zeste homolog 2 inhibitor enhancer
CL2023003811A1 (en) Pikfyve antisense oligonucleotides
BR112023015425A2 (en) URACILA DERIVATIVES AS TRPA1 INHIBITORS
BR112021025618A2 (en) Compound, method of preventing, treating or lessening the severity of a disease, pharmaceutical composition and use of a compound
MA39926B1 (en) Cycloalkyl-linked diheterocycle derivatives
BR112022024751A2 (en) Use of a Phosphodiesterase 10 Inhibitor for the Treatment of Tourette's Syndrome

Legal Events

Date Code Title Description
FB Suspension of granting procedure